These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 17355744
1. Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Sunkara G, Reynolds CV, Pommier F, Humbert H, Yeh C, Prasad P. Curr Med Res Opin; 2007 Mar; 23(3):631-40. PubMed ID: 17355744 [Abstract] [Full Text] [Related]
3. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D. J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525 [Abstract] [Full Text] [Related]
7. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, Humbert H, Sunkara G. Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461 [Abstract] [Full Text] [Related]
8. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. McKenney JM, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling D, Shalwitz RA. J Clin Pharmacol; 2006 Jul; 46(7):785-91. PubMed ID: 16809804 [Abstract] [Full Text] [Related]
9. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study. Rump LC, Baranova E, Okopien B, Weisskopf M, Kandra A, Ferber P. Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834 [Abstract] [Full Text] [Related]
10. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF. J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833 [Abstract] [Full Text] [Related]
11. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. Bhad P, Ayalasomayajula S, Karan R, Leon S, Riviere GJ, Sunkara G, Jarugula V. J Clin Pharmacol; 2011 Jun; 51(6):933-42. PubMed ID: 20852001 [Abstract] [Full Text] [Related]
12. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers. Hedaya MA, Helmy SA. Clin Ther; 2013 Jun; 35(6):846-61. PubMed ID: 23795576 [Abstract] [Full Text] [Related]
13. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Am J Cardiol; 2007 Jul 15; 100(2):222-6. PubMed ID: 17631074 [Abstract] [Full Text] [Related]
14. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, Lloyd P. Clin Pharmacol Ther; 1997 Jan 15; 61(1):35-44. PubMed ID: 9024172 [Abstract] [Full Text] [Related]
15. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson TA. Am J Cardiol; 2004 Nov 01; 94(9):1140-6. PubMed ID: 15518608 [Abstract] [Full Text] [Related]
16. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K. Clin Ther; 2007 Apr 01; 29(4):617-25. PubMed ID: 17617285 [Abstract] [Full Text] [Related]
17. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA, Absalón-Reyes JA, Novoa-Heckel G, de Lago A, Oliva I, Rodríguez Z, González-de la Parra M, Burke-Fraga V, Namur S. Clin Ther; 2007 Jun 01; 29(6):1146-52. PubMed ID: 17692728 [Abstract] [Full Text] [Related]
18. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M. Clin Ther; 2009 Feb 01; 31(2):399-410. PubMed ID: 19302912 [Abstract] [Full Text] [Related]
19. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga RE, Nucci GD, Alam SM, Dham R, Qumaruzaman. Biopharm Drug Dispos; 2003 Jul 01; 24(5):183-9. PubMed ID: 12784317 [Abstract] [Full Text] [Related]
20. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. Blumer J, Batisky DL, Wells T, Shi V, Solar-Yohay S, Sunkara G. J Clin Pharmacol; 2009 Feb 01; 49(2):235-41. PubMed ID: 19179299 [Abstract] [Full Text] [Related] Page: [Next] [New Search]